Affordable Access

deepdyve-link
Publisher Website

Pancreatic cancer genomics

Authors
  • Chang, David K
  • Grimmond, Sean M
  • Biankin, Andrew V1, 2, 3, 4, 5, 6, 7
  • 1 Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate
  • 2 West of Scotland Pancreatic Unit, Glasgow Royal Infirmary
  • 3 The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research
  • 4 St Vincent's Clinical School, Faculty of Medicine, University of NSW
  • 5 Department of Surgery, Bankstown Hospital
  • 6 South Western Sydney Clinical School, Faculty of Medicine, University of NSW
  • 7 Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland
Type
Published Article
Journal
Current Opinion in Genetics & Development
Publisher
Elsevier
Publication Date
Jan 01, 2014
Volume
24
Pages
74–81
Identifiers
DOI: 10.1016/j.gde.2013.12.001
Source
Elsevier
License
Unknown

Abstract

Pancreatic cancer is one of the most lethal malignancies. The overall median survival even with treatment is only 6–9 months, with almost 90% succumbing to the disease within a year of diagnosis. It is characterised by an intense desmoplastic stroma that may contribute to therapeutic resistance, and poses significant challenges for genomic sequencing studies. It is recalcitrant to almost all therapies and consequently remains the fourth leading cause of cancer death in Western societies. Genomic studies are unveiling a vast heterogeneity of mutated genes, and this diversity may explain why conventional clinical trial designs have mostly failed to demonstrate efficacy in unselected patients. Those that are available offer only marginal benefits overall, but are associated with clinically significant responses in as yet undefined subgroups. This chapter describes our current understanding of the genomics of pancreatic cancer and the potential impact of these findings on our approaches to treatment.

Report this publication

Statistics

Seen <100 times